Sapio HealthSapio Health
  • Today
  • Patients
  • Inbox
  • Calendar
Insight
  • Population
  • Quality (QOF)
System
  • Models
  • Data feeds
  • Settings
Practice trajectory
-26%
JD
Dr John Dolittle
Ashford Vale Medical Group
Oracle · 15 patients

Clinical Context Engine

Powered by Horizon One

Miss Chloe Avery, 26

Major medical diagnoses

  • Polycystic ovary syndrome (bilateral, USS-confirmed; biochemical — low SHBG) — on metformin, ?endometriosis being investigated
  • Emotionally unstable personality disorder with recurrent depression (~10 yrs) and history of self-harm/overdose — currently on vortioxetine
  • Recurrent/chronic costochondritis — multiple flares with severe chest pain, several A&E/SDEC attendances to exclude cardiac cause (current presenting issue)
  • Chronic rhinosinusitis / nasal congestion (ENT — ?nasal polyps, reported mould allergy) and migraine

Relevant recent context

  • Recurrent costochondritis dominates recent contacts — repeated fit notes, GTN-style private employer letter (Dec 2025), and ongoing eConsults. Pain severe in flares (up to 10/10, occasional vomiting), exacerbated by return to work/exertion; managed with PRN naproxen + omeprazole.
  • PCOS: seen KCH/PRUH endocrinology, started metformin Nov 2025 → periods more regular, dysmenorrhoea improved; discharged to patient-initiated follow-up (12/12). Endocrine queried endometriosis → gynaecology referral pending (appt ~April 2026).
  • Mental health: long EUPD/depression history; lamotrigine was started by CMHT (Oct 2024) but never re-issued, so she remains on vortioxetine 20mg alone. Multiple ADAPT (Oxleas) psychology assessment appointments offered.
  • Cardiology: rapid-access chest pain clinic declined (atypical, young); direct-access echocardiogram requested Aug 2025 — outcome not on file.
  • ENT: discharged April 2025 for non-attendance at CT paranasal sinuses (could re-refer). NKDA.
  • Outstanding: medication review due (flagged Feb 2026); confirm echo result; chase gynae appointment.

E-consult summary

  • 11 May 2026 — OCR-garbled reason ("contonogitis"); ongoing problem, requests review/examination by Dr Amin. In context most likely a recurrent costochondritis flare.

Past medical history

  • Polycystic ovary syndrome (bilateral)
  • Emotionally unstable personality disorder
  • Recurrent / severe depression (~10 yrs)
  • Suicide & self-harm — overdose 2017, recurrent cutting
  • Costochondritis (recurrent/chronic) — ?pericarditis considered, not confirmed
  • Migraine
  • Insomnia
  • Chronic mechanical low back pain (MRI normal; ?spondyloarthropathy excluded)
  • IBS-type symptoms
  • Recurrent UTI — incl. ESBL E. coli (Feb 2024)
  • Menorrhagia / irregular heavy periods
  • Chronic rhinitis / sinusitis (?nasal polyps)
  • Rosacea; seborrhoeic dermatitis of scalp; scalp hair loss (dermatology-investigated)
  • Recurrent ingrowing toenails (bilateral great toes)

Past surgical history

  • Bilateral great-toenail avulsion with chemical cautery (Oct 2012)
  • Bilateral lateral wedge resection of great toenails (Mar 2012)
  • Multiple minor-surgery excisions/cautery of seborrhoeic keratoses (2022–2023; chest, back, nasolabial fold, vulval region, cheek)
  • (Closed fracture L thumb 2009 — conservative, thumb spica)

Medications

Current / active

  • Vortioxetine 20mg — one daily (on repeat; last issued Feb 2026)
  • Metformin 500mg — one twice daily (for PCOS; started Nov 2025 — KCH endocrine)
  • Tirzepatide (Mounjaro) — private: 10mg weekly per endocrine Oct 2025; 2.5mg issued via Numan Mar 2026
  • Naproxen 250mg — up to TDS, max 1g/day (costochondritis)
  • Omeprazole 20mg — one daily (gastroprotection with NSAID)
  • Mometasone 50microgram/dose nasal spray — on repeat (chronic rhinitis)
  • Melatonin 2mg MR — at night (insomnia/migraine)

Stopped / changed

  • Lamotrigine — started by CMHT Oct 2024 but never re-issued/established; remained on vortioxetine alone
  • Citalopram 10mg — earlier antidepressant, switched to vortioxetine
  • Amitriptyline 10mg — past (sleep/headache)
  • Hydroxyzine 25mg — past (sleep)
  • Ibuprofen 400mg — past (costochondritis, switched to naproxen)
  • Naproxen 500mg BD — past (reduced/changed to 250mg)
  • Rigevidon (COCP) — stopped (mood change, irregular bleeding)
  • Ethinylestradiol 30microgram/drospirenone 3mg (COCP) — past
  • Mefenamic acid 500mg — past (dysmenorrhoea)
  • Sumatriptan 50mg — past PRN (migraine)
  • Ferrous fumarate 210mg — past (low ferritin/hair loss)

New from letters/discharge (note source)

  • Magnesium oxide — OTC, recommended for migraine (ENT, Jan 2025)
  • Dymista nasal spray — recommended (ENT, Jan 2025)
  • Oramorph 10mg — given for chest pain (KCH SDEC, Jul 2025)

Past acute courses — antibiotics (recurrent toenail infections / UTI / sinusitis)

  • Flucloxacillin
  • Co-amoxiclav
  • Amoxicillin
  • Erythromycin
  • Doxycycline
  • Trimethoprim (ESBL-resistant)
  • Nitrofurantoin 100mg MR (ESBL UTI, Feb 2024)
  • Metronidazole

Past topical / other

  • Betamethasone valerate 0.1% scalp application
  • Clobetasol 0.05% scalp application
  • Ketoconazole 2% (Nizoral) shampoo
  • Ivermectin 10mg/g cream (rosacea)
  • Fusidic acid 2% cream
  • Mupirocin 2% nasal ointment
  • Naseptin nasal cream
  • Beclometasone nasal spray
  • Hydrocortisone 1% cream/ointment (± miconazole)
  • Clotrimazole 1% cream
  • Salicylic acid/lactic acid paint (verruca)
  • Chlorhexidine 4% solution (toenail wash)
  • Laxido / ispaghula husk / mebeverine 135mg / Dioralyte (IBS, constipation)
  • Lidocaine injection (minor-surgery local anaesthetic)

Key markers

  • BMI 33.8 kg/m² (Jul 2025); weight 95 kg (Feb 2024) → 84.8 kg (Oct 2025) on Mounjaro
  • BP 126/73 mmHg, pulse 104 (Oct 2025) — normotensive but mild resting tachycardia
  • HbA1c 38 mmol/mol (Jan 2025) — non-diabetic
  • Testosterone 1.3 nmol/L (normal) with low SHBG 20.1 nmol/L → biochemical PCOS; FSH 5.8 / LH 2.1 IU/L, oestradiol 96 pmol/L
  • TFT normal (TSH 2.37, fT4 11.8); prolactin 204 mIU/L, cortisol 256 nmol/L — normal
  • FBC normal (Hb 124–128 g/L, MCV 95); ferritin 43 µg/L (low-normal — relevant to hair loss)
  • U&E normal (creat 71, eGFR >90); LFTs normal
  • Cardiac work-up (SDEC Jul 2025): troponin negative, CRP negative, ECG normal sinus rhythm, CXR clear, WCC 12
  • Note: Hb 108 g/L at UCC Dec 2024 with heavy menstrual bleeding/clots

Last admission

  • 25 Jul 2025 — King's College Hospital, PRUH SDEC / Medical Assessment Day Unit. Sudden central chest pain radiating to upper back, worse lying flat, eased leaning forward, with SOB. ECG normal (no pericarditis), CXR clear, troponin/CRP negative. Impression: musculoskeletal chest pain / costochondritis — discharged same day on NSAID + PPI with safety-netting. (Patient additionally reports a further A&E attendance late Aug 2025 for a similar "attack" — no discharge summary on file.)
Synthesised clinical context — derived from the source record by the Horizon-1 Coding engine.

Trajectory Engine

Powered by Horizon One
Δ burden-0.14
Risk avoided—
Drivers moved100%
Current burden0.48
Latent clinical states
The syndromes shaping this radar. Adjust the cockpit below to see which ones move.
1 active
Metabolic (pre-clinical)
52%worsening
Horizon-1 · Trajectory Radar

10-year projective trajectory

Adjust the cockpit and watch the projection move.

8 axes
BURDEN 1.0HbA1cTriglyceridesBMIHRSBPActivityHDL-CCRP3535353535353535
Today
Projected · 10 yr
Baseline0.48
Projected0.35Δ-0.14
Risk avoided—
For demonstration purposes. Not a diagnostic tool.
Treatment Cockpit · SIM

Personalised to this patient

Toggle to simulate — the radar updates live.

Lifestyle adherence55%

Diet, activity, sleep, medication routine — composite.

0%100%
Physiological decay (10y)40%

Untreated progression pressure from ageing and comorbidity load.

LowHigh
Combined oral contraceptiveHormonal
Combined OCP (daily) · Adherence 93%
Structured lifestyle programmeOther£
Dietitian + activity coach, 12-week block
Activity pattern regressing over 6m — high-leverage now.
NNT 14 · ARR 6.5%
Counterfactual simulation — no change to the patient record.
Clinical ROI
Largest projected axis shifts under current cockpit settings
10y risk volume avoided
—
Activity
Improves
Δ -0.22
(Lower values are closer to healthy manifold)
BMI
Improves
Δ -0.19
(Lower values are closer to healthy manifold)
Triglycerides
Improves
Δ -0.18
(Lower values are closer to healthy manifold)
For demonstration purposes. Not a diagnostic tool.
Value of Information
Most useful next test
BASE 33.0/40
POTENTIAL 33.0/40
Order Now
No tests exceed the policy threshold.
Optional
No optional tests for this profile.
Not Recommended
No tests are currently suppressed.
For demonstration purposes. Not a diagnostic tool.